TREATMENT WITH ANTI ErbB2 ANTIBODIES
AssigneeGenentech, Inc.
InventorsSusan Desmond-Hellmann, Virginia Paton, Steven Shak
Life of this patent
Estimating the term…
Abstract
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.
Claims15
A method for the treatment of a human patient with a cancer characterized by overexpression of ErbB2 receptor, comprising administering a combination of an anti-ErbB2 antibody and gemcitabine, in the absence of an anthracycline derivative, to the human patient in an amount effective to treat the cancer, wherein the treatment increases time to disease progression compared to therapy with gemcitabine alone.
A method for treating a cancer selected from the group consisting of breast cancer, non-small cell lung cancer, pancreatic cancer and bladder cancer characterized by overexpression of ErbB2 receptor, comprising administering a combination of an anti-ErbB2 antibody and gemcitabine, in the absence of an anthracycline derivative, to a human patient in an amount effective to treat the cancer, wherein the antibody is not conjugated with the gemcitabine and the effective amount of the combination is lower than the sum of the effective amounts of the anti-ErbB2 antibody and the gemcitabine, when administered individually, as single agents.
A method for the treatment of a human patient with an ErbB2-expressing cancer, comprising administering a combination of an anti-ErbB2 antibody and gemcitabine, to the human patient in an amount effective to treat the cancer, wherein the treatment increases time to disease progression compared to therapy with gemcitabine alone.
Dependencies are inferred from the claim text.